Neuronetics, Inc. (NASDAQ:STIM) Expected to Announce Quarterly Sales of $13.20 Million

Equities research analysts expect Neuronetics, Inc. (NASDAQ:STIMGet Rating) to announce sales of $13.20 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Neuronetics’ earnings. The lowest sales estimate is $13.10 million and the highest is $13.30 million. Neuronetics reported sales of $12.29 million in the same quarter last year, which would suggest a positive year over year growth rate of 7.4%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Neuronetics will report full-year sales of $59.58 million for the current fiscal year, with estimates ranging from $58.80 million to $60.36 million. For the next fiscal year, analysts expect that the business will report sales of $68.85 million, with estimates ranging from $68.20 million to $69.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Neuronetics.

Neuronetics (NASDAQ:STIMGet Rating) last posted its earnings results on Tuesday, March 8th. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Neuronetics had a negative return on equity of 33.24% and a negative net margin of 56.39%. During the same quarter last year, the firm posted ($0.19) earnings per share.

A number of brokerages have recently issued reports on STIM. Piper Sandler dropped their price target on Neuronetics from $10.00 to $9.00 in a research report on Monday, January 3rd. Zacks Investment Research downgraded Neuronetics from a “buy” rating to a “hold” rating in a research report on Saturday, March 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.06.

In other news, major shareholder Cannell Capital Llc bought 33,400 shares of the company’s stock in a transaction that occurred on Wednesday, April 13th. The stock was bought at an average price of $2.88 per share, for a total transaction of $96,192.00. Following the transaction, the insider now directly owns 3,130,913 shares of the company’s stock, valued at approximately $9,017,029.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP William Andrew Macan sold 11,562 shares of the business’s stock in a transaction that occurred on Monday, January 24th. The stock was sold at an average price of $3.52, for a total value of $40,698.24. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 143,970 shares of company stock valued at $424,338 and sold 48,948 shares valued at $165,469. Insiders own 4.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in STIM. Schroder Investment Management Group lifted its position in Neuronetics by 117.5% in the third quarter. Schroder Investment Management Group now owns 1,762,963 shares of the company’s stock valued at $11,565,000 after purchasing an additional 952,291 shares during the last quarter. Cannell Capital LLC lifted its position in Neuronetics by 58.9% in the third quarter. Cannell Capital LLC now owns 2,085,003 shares of the company’s stock valued at $13,678,000 after purchasing an additional 772,665 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its position in Neuronetics by 55.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 846,574 shares of the company’s stock valued at $3,776,000 after purchasing an additional 300,651 shares during the last quarter. Archon Capital Management LLC lifted its position in Neuronetics by 17.7% in the fourth quarter. Archon Capital Management LLC now owns 1,854,415 shares of the company’s stock valued at $8,271,000 after purchasing an additional 279,220 shares during the last quarter. Finally, Norges Bank bought a new stake in Neuronetics in the fourth quarter valued at approximately $1,174,000. Hedge funds and other institutional investors own 79.48% of the company’s stock.

Shares of STIM remained flat at $$3.01 during trading hours on Wednesday. The stock had a trading volume of 75,324 shares, compared to its average volume of 150,210. The company has a market capitalization of $80.16 million, a PE ratio of -2.51 and a beta of 2.35. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.93 and a current ratio of 7.34. The firm’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $4.12. Neuronetics has a 12-month low of $2.80 and a 12-month high of $17.92.

Neuronetics Company Profile (Get Rating)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.